EnteroMedics announced it has completed the first commercial shipment of the Maestro Rechargeable (RC) System to Device Technologies Pty Ltd., its distribution partner in Australia. This marks a significant milestone for the company, supporting its evolution to a commercial enterprise and its goal of delivering safe, effective and sustainable weight-loss treatments to patients across the globe.

The Maestro RC System delivers VBLOC vagal blocking therapy, which is a first-in-class weight loss treatment that controls both hunger and fullness by blocking the primary nerve regulating the digestive system. VBLOC is designed to be a safer, less invasive treatment for obesity that allows patients to address the lifelong challenges and associated health complications of obesity without sacrificing their wellbeing or comfort. The Maestro RC System has received CE Mark approval for treating obesity and has been listed on the Australian Register of Therapeutic Goods for commercial sale in Australia.

EnteroMedics additionally announced today that it has signed an exclusive, multiyear agreement with leading Middle Eastern medical and diagnostic equipment distributor Bader Sultan & Brothers Co. to commercialize and distribute the Maestro RC System in the Gulf Coast countries. These countries will include Saudi Arabia, Kuwait, Bahrain, Qatar and the United Arab Emirates.

EnteroMedics is a development-stage medical device company specializing in the design and development of devices that utilize neuroblocking technology for the treatment of obesity, metabolic diseases and other gastrointestinal disorders. VBLOC vagal blocking therapy, the company’s proprietary neuroblocking technology, is designed to intermittently block the vagus nerves by using high-frequency, low-energy electrical impulses. These are delivered by the company’s Maestro System, a neuroregulator powered by an integrated rechargeable battery.

For more information, visit the company’s Web site at www.enteromedics.com

Let us hear your thoughts below: